Navigation Links
Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
Date:10/29/2008

Co-founder of and Former Senior Executive at ImClone Brings Substantial Oncology Drug Development Expertise

NEW BRUNSWICK, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today the appointment of Harlan W. Waksal, M.D., 55 to its board of directors. Senesco's board of directors now consists of nine members, seven of whom are independent.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081029/NY42202 )

Dr. Waksal is the President and Sole Proprietor of Waksal Consulting L.L.C., which was founded in 2003 and provides strategic business and clinical development counsel to biotechnology companies. Dr. Waksal co-founded the biotechnology company, ImClone Systems Incorporated, in 1984. He served at ImClone in a variety of senior roles over a 16 year period, beginning in 1987. During his tenures as Chief Operating Officer, from 1987 through 2002, and Chief Executive Officer, from 2002 until 2003, Dr. Waksal was instrumental in moving forward the clinical development program for ERBITUX(R) (cetuximab), an oncology drug now approved in colorectal and head & neck cancers. ERBITUX (cetuximab) is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells, called the epidermal growth factor receptor (EGFR).

"Senesco is very pleased to have Dr. Waksal join our Board," said Rudolf Stalder, Chairman of Senesco's Board. "His significant contribution to the clinical development of Erbitux, and vast knowledge of the oncology space, will provide critical industry insight to Senesco."

"We look forward to working with Dr. Waksal as we move toward our goal of filing an IND for multiple myeloma," said Bruce Galton, President & Chief Executive Officer of Senesco. "We believe his extensive and distinguished wo
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
3. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
4. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
5. Senesco Technologies to Present at BIO 2008 Business Forum
6. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
7. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
8. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
10. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
11. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... D.C. (PRWEB) September 18, 2014 On ... Durbin and Sen. Jim Risch for National Lab Day ... projects from across the national laboratory system. Durbin and ... which aims to increase awareness of the reach of ... technologies and discoveries to address some of our nation's ...
(Date:9/18/2014)... Research and Markets has announced ... Report 2014" report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... albumin market analysis is provided for the international markets ...
(Date:9/18/2014)...  U.S. biotech company Kultevat has strengthened ... technology developed by the Donald Danforth Plant Science ... for applications in production of natural rubber in ... developed under the direction of Roger Beachy , ... of the Danforth Plant Science Center, and is used ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
Breaking Biology Technology:Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... 11 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a ... the early detection of diseases and personalized health ... a agreement allowing Centocor Research & Development, Inc. ... biomarker program. Additional terms of the agreement were ...
... Hovione announced today,that it has agreed with Pfizer to ... This site manufactures,intermediates for Lipitor active pharmaceutical ingredient. , ... had a number of owners starting in 1984 with ... and now Hovione. Over,the last 10 years Pfizer has ...
... McCulley/Cuppan announced today the launch of a new series of web-based ... The web delivered "short" courses are one hour in duration and ... writing skills. , ... Salt Lake City, Utah (PRWEB) ...
Cached Biology Technology:GeneNews provides Centocor access to its osteoarthritis program 2Hovione Buys Pfizer's Loughbeg API Facility 2Hovione Buys Pfizer's Loughbeg API Facility 3McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 2McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 3
(Date:9/18/2014)... their colleagues have built the first smartphone app ... and behavioral trends. In other words, your smartphone ... you don,t -- and how that affects you. ... stress, depression and loneliness to their academic performance, ... for example, to monitor mental health, trigger ...
(Date:9/18/2014)... which have devastated algal forests in the eastern Mediterranean ... basin if their distribution continues to expand as the ... an international team of researchers led by Dr Adriana ... the Mediterranean Institute for Advanced Studies in Spain, is ... of the team surveyed more than 1000 kilometres of ...
(Date:9/18/2014)... Becoming invisible is probably the ultimate form of camouflage: ... you. And this strategy is not as uncommon as ... Maryland Baltimore County, USA, explains that the larval life ... is one part of the anatomy that most creatures ... compound eyes have to shield each individual eye unit ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2
... COLUMBUS, Ohio - For the first time, researchers have found ... therapy agent directly into a single living cell without a ... therapeutic biomolecules through a tiny channel and into a cell ... and his colleagues at Ohio State University describe the technique ...
... terrorized its plant-eating neighbours in South America was a lot ... found. Carnotaurus was a seven-metre-long predator with ... student Scott Persons says made it one of the fastest ... tail bones of Carnotaurus showed its caudofemoralis muscle ...
... , New York, NY (October 14, 2011) Researchers at ... uncovered a vast new gene regulatory network in mammalian cells ... The studies appear in today,s online edition of Cell ... a missing piece in the puzzle of cell regulation and ...
Cached Biology News:Researchers do precise gene therapy without a needle 2Researchers do precise gene therapy without a needle 3Vast hidden network regulates gene expression in cancer 2Vast hidden network regulates gene expression in cancer 3
...
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Biology Products: